hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
=== Oath of neutrality === On 15 March 1900, Lord Roberts proclaimed an amnesty for all burghers, except leaders, who took an oath of neutrality and returned quietly to their homes. It is estimated that between 12,000 and 14,000 burghers took this oath between March and June 1900.
== History == AryoGen Pharmed is the first and largest mAb producer in MENA region with the vision of manufacturing high-quality biosimilar products for patients suffering from life-threatening diseases around the world and improving patient’s quality of life. AryoGen pharmed produces its own Active Pharmaceutical Ingredients (APIs) Using large-scale bioreactors according to cGMP guidelines, which have been approved by PIC/s members. Research and Development unit with laboratory-scale and pilot-scale production lines is equipped with cell culture equipment such as bioreactors and recombinant protein purification Facility. The state-of-the-art manufacturing sites of AryoGen have received major accreditation such as EU GMP European Medicines Agency (EMA). The quality of all products have been certified by the most reputable laboratories around the world. AryoGen Pharmed has several Tech-Transfer projects in different countries such as Turkey, Russia and Tunisia. In addition, the products of AryoGen Pharmed have been exported to different countries in Asia, Africa and Latin America.
A diglyceride, or diacylglycerol (DAG), is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Two possible forms exist, 1,2-diacylglycerols and 1,3-diacylglycerols. Diglycerides are natural components of food fats, though minor in comparison to triglycerides. DAGs can act as surfactants and are commonly used as emulsifiers in processed foods. DAG-enriched oil (particularly 1,3-DAG) has been investigated extensively as a fat substitute due to its ability to suppress the accumulation of body fat; with total annual sales of approximately US$200 million in Japan since its introduction in the late 1990s till 2009.
Hylomorphism is a philosophical doctrine developed by the Ancient Greek philosopher Aristotle, which conceives every physical entity or being (ousia) as a compound of matter (potency) and substantial form (act), with the generic form as immanently real within the individual. The word is a 19th-century term formed from the Greek words ὕλη (hyle: "wood, matter") and μορφή (morphē: "form"). Hylomorphic theories of physical entities have been undergoing a revival in contemporary philosophy, especially since the 2000s.
Sources: en.wikipedia.org
== History == Although many authors had suggested the use of power formulas in sediment transport in the decades preceding Bagnold's work, and in fact Bagnold himself suggested it a decade before putting it into practice in one of his other works, it wasn't until 1966 that R. A. Bagnold tested this theory experimentally to validate whether it would indeed work or not. This was successful and since then, many variations and applications of stream power have surfaced. The lack of fixed guidelines on how to define stream power in this early stage lead to many authors publishing work under the name "stream power" while not always measuring the entity in the same way; this led to partially failed efforts to establish naming conventions for the various forms of the formula by Rhoads two decades later in 1986. Today stream power is still used and new ways of applying it are still being discovered and researched, with a large integration into modern numerical models utilizing computer simulations.
== Uses == Secretin is used in diagnostic tests for pancreatic function; secretin is injected and the pancreatic output can then be imaged with magnetic resonance imaging, a noninvasive procedure, or secretions generated as a result can gathered either through an endoscope or through tubes inserted through the mouth, down into the duodenum. A recombinant human secretin has been available since 2004 for these diagnostic purposes. There were problems with the availability of this agent from 2012 to 2015.
== Research == As of March 2019, oral levoketoconazole (developmental code name COR-003, tentative brand name Recorlev) is phase III clinical trials for the treatment of Cushing's syndrome. Oral levoketoconazole may have a lower risk of liver toxicity than oral ketoconazole.
Sources: en.wikipedia.org
==== Indirect immunofluorescence (IDIF) ==== Patients with high concentration of antibodies show intercellular, intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only present with them inside the cells (intercellular). If the results are negative, perform the additional assays regardless. Cases have been confirmed that reported with initial negative DIF and IDIF tests.
CD38-IN-78c is a drug which acts as a potent and selective inhibitor of the glycoprotein enzyme CD38. In animal studies it boosts levels of nicotinamide adenine dinucleotide (NAD+) in tissues via inhibition of CD38 mediated breakdown of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and has been shown to ameliorate metabolic dysfunction associated with the aging process. It also has potential therapeutic application in the treatment of Alzheimer's disease.
IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. IBA focusses on two business segments: cell selection and protein purification. The company is the original manufacturer and supplier of the Strep-tag/Strep-Tactin technology, an affinity chromatography system developed for protein purification. The method is based on one of the strongest non-covalent interactions in nature, which is the interaction of biotin to streptavidin. An intrinsic binding affinity of the Strep-tag towards Strep-Tactin results in a highly specific interaction, which enables the isolation and purification of sensitive proteins in a native state as wells as intact protein complexes, respectively. The technology was patented by the Max Planck Society (former “Garching Innovations”) and later assigned to IBA. Recently, the method was further developed to be used for cell selection from whole blood or other single cell suspensions.
The first observations and size measurements of nano-particles were made during the first decade of the 20th century. Zsigmondy made detailed studies of gold sols and other nanomaterials with sizes down to 10 nm and less. He published a book in 1914. He used an ultramicroscope that employs a dark field method for seeing particles with sizes much less than light wavelength. There are traditional techniques developed during the 20th century in interface and colloid science for characterizing nanomaterials. These are widely used for first generation passive nanomaterials specified in the next section. These methods include several different techniques for characterizing particle size distribution. This characterization is imperative because many materials that are expected to be nano-sized are actually aggregated in solutions. Some of methods are based on light scattering. Others apply ultrasound, such as ultrasound attenuation spectroscopy for testing concentrated nano-dispersions and microemulsions. There is also a group of traditional techniques for characterizing surface charge or zeta potential of nano-particles in solutions. This information is required for proper system stabilization, preventing its aggregation or flocculation. These methods include microelectrophoresis, electrophoretic light scattering, and electroacoustics. The last one, for instance colloid vibration current method is suitable for characterizing concentrated systems.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.